

Biologic DMARD Access and Medication Cost-related Nonadherence in Rheumatology Patients in Canada: A Cross-sectional Survey

Anne Marie Holbrook, MD, PharmD, MSc, FRCPC (ORCID 0000-0002-3371-4187)^{1,2}; Avrilynn Ding MD, (ORCID 0000-0002-1157-1170)³; Sue Troyan²; Sandra Costa²; Mark Matsos⁴; Michael R. Law⁵, Selena Gong⁶; Apurva Dixit⁷; Gary Foster (ORCID 0000-0003-4716-3539)⁸; Nader Khalidi⁴

¹Division of Clinical Pharmacology and Toxicology, Department of Medicine, McMaster University, Hamilton, Canada; ²Clinical Pharmacology & Toxicology Research, Research Institute of St Joes Hamilton, St Joseph's Healthcare Hamilton, Hamilton, Canada; ³Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada; ⁴Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, Canada; ⁵Centre for Health Services and Policy Research, School of Population and Public Health, UBC, Vancouver, Canada; ⁶Institute of Medical Science, University of Toronto, Toronto, Canada; ⁷Faculty of Medicine, University of Toronto, Toronto, Canada; ⁸Biostatistics Unit, Research Institute of St Joes Hamilton, St Joseph's Healthcare Hamilton, Hamilton, Canada

Conflict of Interest:

M Law has consulted for Health Canada, Health Employees' Union, and the Conference Board of Canada, and provided expert witness testimony for the Attorney General of Canada and the Federation of Post-Secondary Educators. N Khalidi reports receiving research support on unrelated topics from Roche, BMS, Abbvie, and Sanofi. A Holbrook, A Ding, S Troyan, S Costa, G Foster, S Gong, A Dixit and M Matsos declare no COI.

Corresponding Author

Dr Anne M Holbrook, MD, PharmD, MSc, FRCPC
Director, Division of Clinical Pharmacology & Toxicology
SJHH G623, 50 Charlton Ave East
Hamilton, ON L8N 4A6
holbrook@mcmaster.ca

Abstract

Background: Cost-related nonadherence to prescription medications affects many Canadians and is associated with negative self-perceptions of health. Biologic disease modifying anti-arthritis drugs (bDMARDs) are costly drugs recommended for certain patients with rheumatoid or psoriatic arthritis and ankylosing spondylitis. We investigated access and cost-related nonadherence (CRN) to bDMARDs compared to other therapies for such patients in Ontario.

Methods: We conducted a cross-sectional telephone survey of adult patients recruited from two academic rheumatology practices in Hamilton, Ontario, asking demographic and socioeconomic characteristics, drug plan coverage, medication cost-related cutbacks, opinions on the value of bDMARDs, and assistance with costs from health professionals. CRN was defined by patient self-report of not using or using less than prescribed amount of medication, due to cost.

Results: 104 patients (mean age (SD) 61(12) years) participated, including 77 (74%) women, 57 (54.8%) taking bDMARDs, and 27 (25.9%) with household income <\$40,000 annually. CRN was reported by 19 (18.3%) participants with no significant difference between those taking versus not taking bDMARDs (risk difference (95% CI): -0.10 (-0.25, 0.04); p=0.19). 37 (64.9%) of those taking bDMARDs reported that they would not take them if they had to pay the full cost. Overall, few patients reported that they would ask their doctor (17.3%) or pharmacist (15.4%) for help with reducing prescription costs.

Conclusion: CRN prevalence was relatively high amongst these rheumatology patients despite access to public and private funding mechanisms. Patients expressed a reluctance to ask their doctor or pharmacist for help in reducing their medication costs.

Introduction

Adherence to chronic medication internationally is notoriously poor, on average at approximately 50% after six to 12 months, with 30% of patients not even picking up the prescription (Anderson et al., 2020; Ho et al., 2009; Osterberg & Blaschke, 2005). The cost of prescription medications is thought to be a barrier for many patients to access the healthcare that they need (Tang et al., 2014). Cost-related nonadherence (CRN) is defined as medication underuse because of cost; this includes unfilled prescriptions, delayed prescriptions, taking smaller doses or less frequent doses than prescribed (Law et al., 2018). Not only is poor adherence associated with more adverse outcomes for patients, it also unnecessarily inflates health care spending because of wastage (Heisler et al., 2010; Kennedy & Morgan, 2009). In Canada, CRN to medications range from 5.1% to 10.2%, with factors predicting CRN including high out-of-pocket spending, low income or financial flexibility, lack of drug insurance, younger age, and poorer health (Holbrook et al., 2021).

Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are the more common inflammatory arthritides and amenable to biologic disease modifying anti-rheumatic drugs (bDMARDs). Each disease has other treatment options including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, conventional DMARDs (cDMARDs) (Gossec et al., 2016; Rohekar et al., 2015; Singh et al., 2016). Systematic reviews do not show superiority of bDMARDs compared to combinations of cDMARDs for RA, but are preferred to cDMARDs for severe PsA and for patients with AS where NSAIDs provide insufficient benefit (Saad et al., 2008; Wu et al., 2015).

Since biologic drugs are now the single most costly group of medications for public drug plans in Canada, their judicious use is required (CIHI, 2019). Most bDMARDs are covered by Ontario's public drug benefit plan (OPDP) through a process called 'frequently requested exceptional access' which requires communication by prescribers to OPDP as to how the individual patient meets specific access criteria (Ministry of Health, 2020). The criteria for public plan reimbursement involve in each case the documentation of failure of two previous conventional therapies or combinations, and renewal requires documentation of improvement with bDMARD use (Ministry of Health, 2020). Even with access restricted to only these situations approaching cost-effectiveness, the bDMARDs are estimated to cost approximately \$300 million annually for rheumatologic conditions in Ontario (Tadrous M et al., January 2020. DOI 10.31027/ODPRN.2020.01).

Our objective in this study was to investigate bDMARD access, adherence and opinions regarding value and costs, for patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis cared for in academic rheumatology practices.

Methods

We designed a cross-sectional survey study using a questionnaire delivered by trained research staff by telephone. The study was approved by Hamilton Integrated Research Ethics Board (HiREB #11-077). Reporting followed the guidelines of the STROBE adaptation for cross-sectional surveys (Equator Network, 2020; von Elm E).

The setting was the practices of two full-time rheumatology specialists in Hamilton, Ontario, Canada. These practices draw referrals from a regional catchment of approximately two million people. Both specialists reported having detailed knowledge of bDMARD drug plan funding processes.

Inclusion criteria were adults age 18 years or older with one of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS). Exclusion criteria included patients not fluent in English with no accessible translator, too frail, or significant cognitive impairment. Potentially eligible patients were first screened for presence of exclusion criteria by their rheumatologist, who sent an information letter about the study by mail to the remaining group, asking them to reply if interested in participating. Recruitment ended in 2016.

Once informed consent was obtained, the questionnaire itself took 15 to 30 minutes to complete. We asked about demographic and socioeconomic characteristics (education level, annual household income), prescription medication used for arthritis, drug plan coverage (co-pay, deductibles, caps, etc) for

prescription medications, out-of-pocket expenditure for prescriptions and other medications, cost-related medical and nonmedical cutbacks, opinions on the value for money of bDMARDs, and requests for assistance with costs from health professionals.

Questions related to cost-related nonadherence were adapted from our previous survey on CRN (Holbrook A, 2020; Zheng B, 2012) which were subsequently adapted for the Canadian Community Health Survey (Law et al., 2012; Law et al., 2018). Participants were asked about leaving prescriptions unfilled, delaying picking up a prescription, not filling a prescription, skipping doses, lowering doses, or substituting prescribed medication with a cheaper alternative.

The main analyses were descriptive. CRN was based on the 6 questions described above, each with scoring options of never=zero, rarely=one, sometimes=two, often=three, and always=four. Total CRN scores were calculated for each participant, with highest possible score of 24. CRN was defined as a response of at least “sometimes” to one or more of the six questions (e.g., total score two or more). For modeling, we used a method to estimate risk differences (Spiegelman & Hertzmark, 2005), to be able to characterize absolute differences between groups. Univariate modeling was used to examine age, income, insurance coverage, medication status, co-payment and out-of-pocket expenses (defined as the amount that the patient paid for prescription medication that was not reimbursed) as possible predictors of CRN as a dichotomized variable (total CRN \geq two versus $<$ two). Multivariable modeling was planned if there were sufficient numbers in each score category. Data analyses were performed using SAS v9.4 (SAS Institute, Inc., Cary, North Carolina).

Results

Of approximately 400 patients who met inclusion criteria and were mailed invitation letters to participate by their rheumatologist, 104 patients participated in the study. Detailed participant characteristics are provided in Table 1. 77 (74.0%) were female, mean age was 60.8 years old (standard deviation [SD] 12.1), 62 (59.6%) had at least some post-secondary school education and 27 (25.6%) reported household income as less than \$40,000 annually. Drug coverage included a mix of private and public drug plans, with only four (3.8%) participants reporting entirely self-pay. 57 (54.8%) participants were taking a bDMARD, compared to 47 (45.2%) not taking a bDMARD. Patients receiving bDMARDs were more likely to be female (80.7% vs 66.0%) and under 65 years of age (75.4% vs 38.3%). A majority of respondents (88 (84.6%)) paid \$100 or less per month out-of-pocket for all prescription medications. This included 50/57 (87.7%) patients using bDMARDs and 38/47 (80.9%) patients not using bDMARDs. No patient taking bDMARDs paid the full out-of-pocket cost for their medication.

Nineteen of 104 (18.3%) participants including 13/57 (22.8%) taking bDMARDs and 6/47 (12.8%) not taking bDMARDs met our definition of CRN (a score of two or more on one or more domain), chi-square $p = 0.187$. Univariable analyses identified predictors of CRN as age (6.9% increase in likelihood of CRN for every 10 year decrease in age, $p=0.010$), out-of-pocket expenditure of \$100 or more compared to $<$ \$20 per year, $p=0.007$, and income of $<$ \$40,000 compared to \geq \$40,000 per year, $p=0.035$ (details in Table 3).

More patients taking bDMARDs compared to patients not taking bDMARDs (13 (22.8%) vs six (12.8%), $p = 0.21$) used one or more strategies to cover the cost of medication, most commonly cutting back on leisure and recreation items, followed by clothing and food (Table 2). 46 (80.7%) patients taking bDMARDs reported that the bDMARD effectiveness and safety was worth their cost, but 37 (64.9%) also reported that they would not be taking bDMARDs if they had to pay the full cost themselves. Those who were prescribed biologics were more likely to report that their physicians asked how much they paid for drugs and were more likely to consider the cost of their medications, compared to those not prescribed a biologic, 47 (82.4%) versus 22 (46.8%), and 37(64.9%) versus 24 (51.1%) respectively. However, only a small number of patients, 18 (17.3%) overall, 14 (24.6%) taking bDMARDs versus four (8.5%) not taking bDMARDs, asked for assistance with drug costs from their physician, and 16 (15.3%) overall, 12 (21.1%) using bDMARDs versus four (8.5%) not taking bDMARDs, from their pharmacist.

Discussion

Our cross-sectional examination of access to expensive bDMARDs for their most common rheumatologic indications for patients in academic practices, revealed that the self-reported physician awareness of public drug plan funding criteria and requirements for bDMARDs was used regularly to gain access for patients. While the prevalence of cost-related nonadherence in this group of patients was higher than the 9.6% average for Canadians receiving prescriptions, there was no significant difference between patients on biologics and those not taking biologics (Heidari et al., 2018). Although most patients taking bDMARDs felt that their benefit was worth the cost, only a minority would continue taking them if paying the full cost.

A systematic review of costs and medication adherence for patients with RA found that rates of adherence ranged from 18.2% to 48% at one year post-initiation, and out-of-pocket costs were the main predictors (Heidari et al., 2018). These studies included all medications for arthritis. Given that bDMARDs are approximately five times more expensive than cDMARD combinations, CRN is likely to be more common for these patients. Several studies suggest that 1-year rates of nonadherence to bDMARDs in international cohorts with inflammatory arthritides, are high at 20% to 54%, (Dalén et al., 2016; Stolshek et al., 2018) but most do not address cost-related nonadherence specifically. A survey of older adults with RA in Medicare reported CRN in 18.4%, a rate three and a half times those with other chronic diseases, and these patients were two and a half times more likely to spend less on basic necessities (Harrold et al., 2013). Although bDMARDs are in the treatment algorithms of RA, PsA and AS, their expense has modified their place in therapy (Mian et al., 2019). A review of patient attitudes and opinions showed some ambivalence towards the drugs, with a sense of privilege involved in access, but concern because of their cost and their perceived toxicity which was influenced by the experience of patients' acquaintances rather than by the summary evidence (Kelly et al., 2018).

Our study is limited by a small sample size, a single urban setting and restriction to academic practices, and lack of details on medications for those patients not taking bDMARDs, making it difficult to generalize to other types of settings.

The implications of this study are several. Clinicians need to regularly check on patients' medication adherence and drug insurance coverage, and offer assistance in reducing medication costs. Policy makers in Ontario may be reassured that these patients can get access to bDMARDs but should be concerned by the high rate of CRN.

Despite good physician advocacy leading to high levels of access to public and private plan coverage for all types of bDMARDs, CRN prevalence was still relatively high amongst these patients and did not differ between those taking versus not taking bDMARDs. This study should be replicated in a larger sample of patients.

Acknowledgments and Affiliations

The study was funded through a Canadian Institute of Health Research grant titled “Cost related Non-adherence to prescription drugs; A Multi-Method Study” (PI, Michael Law).

References

- Anderson, L. J., Nuckols, T. K., Coles, C., Le, M. M., Schnipper, J. L., Shane, R., Jackevicius, C., Lee, J., Pevnick, J. M., & Group, M. o. t. P.-D. 2020. A systematic overview of systematic reviews evaluating medication adherence interventions. *American Journal of Health-System Pharmacy*, 77(2), 138-147. <https://doi.org/10.1093/ajhp/zxz284>
- CIHI. (2019). *Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Programs*. <https://www.cihi.ca/sites/default/files/document/pdex-report-2019-en-web.pdf>
- Dalén, J., Svedbom, A., Black, C. M., Lyu, R., Ding, Q., Sajjan, S., Sazonov, V., & Kachroo, S. 2016. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. *Rheumatol Int*, 36(7), 987-995. <https://doi.org/10.1007/s00296-016-3423-5>
- Equator Network. 2020. *Checklist for reporting a cross sectional study*. Retrieved March 3, 2021 from <https://www.goodreports.org/reporting-checklists/strobe-cross-sectional/>
- Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G., Cañete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., van der Heijde, D. 2016. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Annals of the Rheumatic Diseases*, 75(3), 499-510. <https://doi.org/10.1136/annrheumdis-2015-208337>
- Harrold, L. R., Briesacher, B. A., Peterson, D., Beard, A., Madden, J., Zhang, F., Gurwitz, J. H., & Soumerai, S. B. 2013. Cost-related medication nonadherence in older patients with rheumatoid arthritis. *J Rheumatol*, 40(2), 137-143. <https://doi.org/10.3899/jrheum.120441>
- Heidari, P., Cross, W., & Crawford, K. 2018. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review. *Seminars in Arthritis and Rheumatism*, 48(1), 12-21. <https://doi.org/https://doi.org/10.1016/j.semarthrit.2017.12.010>
- Heisler, M., Choi, H., Rosen, A. B., Vijan, S., Kabeto, M., Langa, K. M., & Piette, J. D. 2010. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. *Med Care*, 48(2), 87-94. <https://doi.org/10.1097/MLR.0b013e3181c12e53>
- Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. 2009. Medication adherence: its importance in cardiovascular outcomes. *Circulation*, 119(23), 3028-3035. <https://doi.org/10.1161/CIRCULATIONAHA.108.768986>
- Holbrook A, W. M., Lee M, Chen Z, Garcia M, Nguyen L, Ford A, Manji S, Law MR. 2020. Cost-Related Medication Nonadherence in Canada: A Systematic Review of Prevalence, Predictors, and Clinical Impact. *Systematic Reviews*, Under Review. <https://orcid.org/0000-0002-3371-4187>
- Holbrook, A. M., Wang, M., Lee, M., Chen, Z., Garcia, M., Nguyen, L., Ford, A., Manji, S., & Law, M. R. 2021. Cost-related medication nonadherence in Canada: a systematic review of prevalence, predictors, and clinical impact. *Systematic Reviews*, 10(1), 11. <https://doi.org/10.1186/s13643-020-01558-5>
- Kelly, A., Tymms, K., Tunnicliffe, D. J., Sumpton, D., Perera, C., Fallon, K., Craig, J. C., Abhayaratna, W., & Tong, A. 2018. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. *Arthritis Care Res (Hoboken)*, 70(4), 525-532. <https://doi.org/10.1002/acr.23329>
- Kennedy, J., & Morgan, S. 2009. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries. *Clin Ther*, 31(1), 213-219. <https://doi.org/10.1016/j.clinthera.2009.01.006>
- Law, M. R., Cheng, L., Dhalla, I. A., Heard, D., & Morgan, S. G. 2012. The effect of cost on adherence to prescription medications in Canada. *Canadian Medical Association Journal*, 184(3), 297-302. <https://doi.org/10.1503/cmaj.111270>
- Law, M. R., Cheng, L., Kolhatkar, A., Goldsmith, L. J., Morgan, S. G., Holbrook, A. M., & Dhalla, I. A. 2018. The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey. *CMAJ Open*, 6(1), E63-e70. <https://doi.org/10.9778/cmajo.20180008>
- Mian, A., Ibrahim, F., & Scott, D. L. (2019). A systematic review of guidelines for managing rheumatoid arthritis. *BMC Rheumatol*, 3, 42. <https://doi.org/10.1186/s41927-019-0090-7>
- Ministry of Health. 2020. *Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs*. http://www.health.gov.on.ca/en/pro/programs/drugs/docs/frequently_requested_drugs.pdf
- Osterberg, L., & Blaschke, T. 2005. Adherence to medication. *N Engl J Med*, 353(5), 487-497. <https://doi.org/10.1056/NEJMr050100>
- Rohekar, S., Chan, J., Tse, S. M., Haroon, N., Chandran, V., Bessette, L., Mosher, D., Flanagan, C., Keen, K. J., Adams, K., Mallinson, M., Thorne, C., Rahman, P., Gladman, D. D., & Inman, R. D. 2015. 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. *J Rheumatol*, 42(4), 654-664. <https://doi.org/10.3899/jrheum.141000>

- Saad, A. A., Symmons, D. P. M., Noyce, P. R., & Ashcroft, D. M. 2008. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. *J Rheumatol*, 35(5), 883-890. <http://europepmc.org/abstract/MED/18381787>
- Singh, J. A., Saag, K. G., Bridges Jr., S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., Curtis, J. R., Furst, D. E., Parks, D., Kavanaugh, A., O'Dell, J., King, C., Leong, A., Matteson, E. L., Schousboe, J. T., McAlindon, T. 2016. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research*, 68(1), 1-25. <https://doi.org/10.1002/acr.22783>
- Spiegelman, D., & Hertzmark, E. 2005. Easy SAS calculations for risk or prevalence ratios and differences. *Am J Epidemiol*, 162(3), 199-200. <https://doi.org/10.1093/aje/kwi188>
- Stolshek, B. S., Wade, S., Mutebi, A., De, A. P., Wade, R. L., & Yeaw, J. 2018. Two-year adherence and costs for biologic therapy for rheumatoid arthritis. *Am J Manag Care*, 24(8 Spec No.), Sp315-sp321.
- Tadrous M, McCormack D, Martins D, Kitchen S, Singh, A., & Gomes, T. January 2020. DOI 10.31027/ODPRN.2020.01). *Current and Prospective Utilization of Innovator Biologics and Biosimilars in Ontario*. Toronto: Ontario Drug Policy Research
- Tang, K. L., Ghali, W. A., & Manns, B. J. 2014. Addressing cost-related barriers to prescription drug use in Canada. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 186(4), 276-280. <https://doi.org/10.1503/cmaj.121637>
- von Elm E, A. D., Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. *The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*. <https://www.goodreports.org/strobe-cross-sectional>
- Wu, V., Chan, O., Maxwell, S. R., Levine, M. A., Perri, D., Sebalt, R. J., Baw, B., & Holbrook, A. 2015. Development and Validation of the McMaster Prescribing Competency Assessment for Medical Trainees (MacPCA). *J Popul Ther Clin Pharmacol*, 22(2), e173-178. <https://www.ncbi.nlm.nih.gov/pubmed/26365356>
- Zheng B, P. A., Fulford M, Holbrook A. 2012. Cost related nonadherence to prescription medication in Ontario. *Journal of Population Therapeutics and Clinical Pharmacology*, 19(2), e239-e247.

Table 1. Baseline Characteristics

Characteristics	All Patients (n=104)	Patients taking bDMARDS (n=57)	Patients not taking bDMARDS (n=47)
Age, yr , mean (SD) (Minimum, Maximum)	61 (12) (24, 86)	56 (12) (24, 78)	66 (10) (41, 86)
Sex Male† Female	27 (26) 77 (74)	11 (19) 46 (81)	16 (34) 31 (66)
Highest Education Less than high school Graduated high school Some post-secondary Graduated university Post-graduate	12 (12) 30 (29) 35 (34) 16 (15) 11 (11)	6 (11) 12 (21) 23 (40) 12 (21) 4 (7)	6 (13) 18 (38) 12 (26) 4 (9) 7 (15)
Household Income (\$/yr) Less than 20,000 20,000 - 39,999 40,000 - 69,999 70,000 – 100,000 Greater than 100,000 Refused/No response	7 (6.7) 20 (19.2) 33 (31.7) 15 (14.4) 24 (23.1) 5 (4.8)	4 (7) 15 (26) 14 (25) 10 (18) 13 (23) 1 (2)	3 (6) 5 (11) 19 (40) 5 (11) 11 (23) 4 (9)
Out-of-Pocket Rx Expense (\$/mo) 0-19 20-100 101-200 201-300 >300 Refused/No response	52 (50.0) 36 (34.6) 9 (8.7) 1 (1.0) 2 (1.9) 4 (3.8)	34 (59.6) 16 (28.1) 4 (7.0) 1 (1.8) 1 (1.8) 1 (1.8)	18 (38.3) 20 (42.6) 5 (10.6) 0 (0) 1 (2.1) 3 (6.4)
Drug Insurance Coverage§ Only private coverage Only government coverage Government and private Full Out-of-Pocket Unknown	47 (45.2) 29 (27.9) 23 (22.1) 4 (3.8) 1 (1)	32 (56.1) 14 (24.6) 10 (17.5) 0 (0) 1 (1.8)	15 (31.9) 15 (31.9) 13 (27.7) 4 (8.5) 0 (0)

† Data cells are number (%) unless otherwise specified

§ Drug insurance coverage referred to the arthritis drugs only.

Table 2. Cost-related Non-adherence Results[†]

Characteristics	All Patients (n=104)	Patients taking bDMARDS (n=57)	Patients not taking bDMARDS (n=47)
CRN Questionnaire[‡]			
Left a prescription unfilled because of cost	5(4.8)	4(7.0)	1(2.1)
Delayed filling a prescription because of cost	8(7.7)	7(12.3)	1(2.1)
Decided not to fill a prescription because of cost	5(4.8)	5(8.8)	0(0)
Skipped doses of prescription medications because of cost	4(3.9)	3(5.3)	1(2.1)
Took lower doses of prescription medication because of costs	4(3.9)	2(3.5)	2(4.3)
Used another cheaper medication instead because of cost	7(6.7)	2(3.5)	5(10.6)
Total CRN score ≥ 2	19 (18.3)	13 (22.8)	6 (12.8)
Areas cut back to cover prescription medication costs (all that apply)			
None	84 (80.8)	43 (75.4)	41 (87.2)
Leisure	15 (14.4)	9 (15.8)	6 (12.8)
Clothing	9 (8.6)	7 (12.3)	2 (4.3)
Food	5 (4.8)	5 (8.8)	0 (0)
Other (car/transportation, utilities, rent)	5 (4.8)	5 (8.8)	0 (0)
Assistance with prescription costs			
Doctors ask how much you pay for prescriptions	69 (66.3)	47 (82.5)	22 (46.8)
Doctors consider cost of medications	61 (58.7)	37 (64.9)	24 (51.1)
I would ask Physician for help with cost	18 (17.3)	14 (24.6)	4 (8.5)
I would ask Pharmacists for help with cost	16 (15.4)	12 (21.1)	4 (8.5)

[†] Data cells are number (%) unless otherwise specified

[‡] Defined as a score of 2 (sometimes) or more frequently

Table 3. Univariable Analyses of Predictors of CRN Total Score

Variable	Comparison	Risk Difference (95 CI)	p-value
Age	Increase in 10 years	-0.069 (-0.121, -0.017)	0.010
Household Income (\$/yr)	< \$40,000 vs ≥ \$40,000	0.208 (0.015, 0.402)	0.035
	< \$70,000 vs ≥ \$70,000	0.089(-0.059, 0.236)	0.241
Sex	Male vs Female	-0.097 (-0.246, 0.053)	0.204
Biologics use	Yes vs No	0.100 (-0.044, 0.245)	0.174
Out-of-pocket expense (\$/mo)	\$100+ vs <\$20	0.404 (0.110, 0.698)	0.007
	\$20-\$99 vs <\$20	0.071 (-0.075, 0.216)	0.343